Clinical trials: Healthy Adult Immune Response
Influenza A Subtype H7N7 Infection
Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults
H7N7 is one type of influenza virus that may pose a threat to humans if an outbreak occurs. This study will evaluate the safety and immune response to an H7N7 vaccine in people who have previously received a live attenuated…
- Trial name
- NCT01534468
- Testing
- Monovalent Influenza Subvirion Vaccine, H7N7
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis
Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination
The purpose of this research is to further study the tuberculosis (TB) vaccine, Bacillus Calmette Guérin (BCG). The goal of this study is to evaluate whether the BCG vaccine is more effective in preventing TB in adults if it is…
- Trial name
- NCT01119521
- Testing
- BCG strain Danish, Isoniazid
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Viral Infections
A Study of Intranasal LMN-1001 in Healthy Adults
The purpose of this study is to optimize the tolerability of LMN-1001 relative to its ability to activate the host immune response. LMN-1001 is an investigational dry powder containing recombinant interferon lambda (IFN-λ).
- Trial name
- NCT07852208
- Testing
- LMN-1001
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Lumen Bioscience, Inc.
HIV Infections
Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)
This is an extension of the HVTN 073/SAAVI 102 study. This study will evaluate the safety and immune response to an HIV envelope protein vaccine boost in people who have previously received the SAAVI DNA-C2 and SAAVI MVA-C…
- Trial name
- NCT01423825
- Testing
- Sub C gp140 Vaccine, MF59C.1 Adjuvant, Sodium chloride
- Where
- 4 sites in United States, South Africa
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prevention of Influenza
Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults
This clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that…
- Trial name
- NCT03160118
- Testing
- Seasonal,quadrivalent,influenza vaccine
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Streptococcal Pharyngitis
Stopping Strep Throat With Antibodies in Healthy Adults.
This research group has previously established a safe and reliable model of experimental human streptococcal pharyngitis (a 'strep throat' human challenge model).
- Trial name
- CHIVAS-IgG (NCT07864350)
- Testing
- Streptococcus pyogenes M1 challenge strain, Intravenous immunoglobulin (IVIG)
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Influenza
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further…
- Trial name
- NCT00192309
- Testing
- CAIV-T, TIV
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
HIV Infections
Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
To prevent HIV infection, a vaccine that produces strong HIV-specific humoral (B-cell) and cellular (T-cell) immune system responses is desirable.
- Trial name
- NCT00073216
- Testing
- Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infections, Meningococcal
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing…
- Trial name
- NCT00356369
- Testing
- meningococcal ACWY (vaccine), Mencevax™ ACWY
- Where
- 3 sites in Philippines, Saudi Arabia
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Polio Immunity
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine.
- Trial name
- NCT07688369
- Testing
- Recombinant Poliomyelitis Vaccine (rPV), Inactivated Poliomyelitis Vaccine (IPOL)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Virus Diseases
A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of a self-amplifying mRNA (SAM) lipid nanoparticle (LNP) platform with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike…
- Trial name
- NCT04758962
- Testing
- 1 µg CoV2 SAM (LNP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
Evaluating the Safety and Immune Response of an Adenovirus-Based HIV Vaccine in HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and immune response of an adenovirus-based HIV vaccine in HIV-uninfected adults.
- Trial name
- NCT01103687
- Testing
- Ad26.ENVA.01 (rAd26)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Vaccines, Marburg Virus Disease
Ebola and Marburg Virus Vaccines
This study will determine if experimental vaccines to prevent Ebola virus infection and Marburg virus infection are safe and what side effects, if any, they cause.
- Conditions
- Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus
- Trial name
- NCT00605514
- Testing
- VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults
The purpose of this study is to evaluate the safety and immune response to three DNA vaccines and a MVA-CMDR vaccine that may boost the immune response to the DNA vaccines in healthy, HIV-uninfected adults.
- Trial name
- NCT02296541
- Testing
- DNA Nat-B env, DNA CON-S env, DNA Mosaic env
- Where
- 7 sites in United States, Switzerland
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza Viral Infections
Single Dose Texas 2017 (H3N2) Challenge Study
The overall objective of the present study is to utilize the recombinant H3N2 (A/Texas/71/2017 (H3N2, clade 3C3a)) influenza virus for a controlled human infection model to study host responses to influenza virus with the aim of…
- Trial name
- NCT06476275
- Testing
- Influenza A/Texas/71/2017 (H3N2)
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Duke University
Encephalitis, Japanese Encephalitis
A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults.
- Trial name
- NCT00981175
- Testing
- Live attenuated Japanese encephalitis virus, then ChimeriVax diluent, ChimeriVax diluent, then Live attenuated Japanese encephalitis virus
- Where
- Australia
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- Sanofi
Tuberculosis
A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402
Healthy adults received BCG on Study Day -84, followed by randomization on Study Day 0 to receive 2 booster doses in a blinded fashion of either AERAS-402 (N=9) or placebo (N=2) on Study Days 0 and 28.
- Trial name
- C-021-402 (NCT02375256)
- Testing
- AERAS-402, BCG (1-8 x105 cfu ID)
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Aeras
Influenza
Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults
Background: Influenza, or "flu", is a very common infectious respiratory disease. Researchers want to develop a vaccine against flu. Vaccines teach the body to fight or prevent an infection.
- Trial name
- NCT03186781
- Testing
- VRC-FLUNPF081-00-VP (HA-F A/Sing), VRC-FLUDNA082-00-VP (DNA A/Sing)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningococcal Immunisation (Healthy Volunteers)
Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Primary Objective: To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus…
- Trial name
- NCT04084769
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine, Meningococcal Group B vaccine (Trumenba®), Meningococcal group B vaccine (Bexsero®)
- Where
- 30 sites in United States, Puerto Rico
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Malaria
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Background: People with malaria often show altered immune responses to many illnesses and vaccines. This means that the malaria might cause immune suppression. It is not clear how or which vaccines are impacted by malaria.
- Trial name
- NCT02544048
- Where
- Mali
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)